Medivation (MDVN) Shares are Up 0.07%

On a relative basis, the stock has outperformed the S&P 500 by 22.9% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.07% in the last 1 week, and is up 20.41% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 1.96% and the 50-Day Moving Average is 16.05%.The 200 Day SMA reached 54.27% Medivation, Inc. is up 36.31% in the last 3-month period. Year-to-Date the stock performance stands at 67.29%.


Medivation (MDVN) : 14 Wall Street analysts covering Medivation (MDVN) believe that the average level the stock could reach for the short term is $71.82. The maximum price target given is $82 and the minimum target for short term is around $40, hence the standard deviation is calculated at $12.35.

Company shares have received an average consensus rating of Hold for the current week Medivation (NASDAQ:MDVN): stock was range-bound between the intraday low of $80.87 and the intraday high of $81.09 after having opened at $81.04 on Fridays session. The stock finally closed in the red at $81.04, a loss of -0.22%. The stock remained in the red for the whole trading day. The total traded volume was 5,722,621 shares. The stock failed to cross $81.09 in Fridays trading. The stocks closing price on Thursday was $80.87.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *